31 C
Vientiane
Tuesday, April 29, 2025
spot_img
Home Blog Page 689

Nisun International Announces Preliminary 2024 Financial Guidance and Strategic Business Updates

Company Anticipates Return to Growth in 2025

SHANGHAI, Jan. 24, 2025 /PRNewswire/ — Nisun International Enterprise Development Group Co., Ltd (“Nisun International” or the “Company”) (Nasdaq: NISN), a technology and industry driven integrated supply chain solutions provider, today announced its preliminary revenue and earnings guidance for fiscal year 2024, along with key strategic decisions that position the Company for long-term growth and profitability.

PRELIMINARY 2024 FINANCIAL GUIDANCE

  • Revenue: The Company expects to report revenues in the range of USD 300 million to USD 350 million.
  • Net Income: The Company anticipates net income in the range of USD 11 million to USD 15 million.
  • EPS: The Company anticipates EPS in the range of USD 2.6 USD 3.6.
  • Annual Report: Nisun International expects to release its annual report before the end of April 2025.

“Our preliminary forecasts underscore the progress we are making in reshaping our business and highlight our commitment to enhancing shareholder value,” stated Xin Liu, Chief Executive Officer of Nisun International.

STRATEGIC REVIEW AND BUSINESS REALIGNMENT

Following a comprehensive review of all business segments, Nisun International has decided to reduce selected supply chain trading businesses characterized by low margins and high capital requirements. This move will enable the Company to better allocate resources and capital toward areas offering higher returns and sustainable growth.

FOCUS ON SUPPLY CHAIN FINANCING SOLUTIONS

Going forward, Nisun International will concentrate more on supply chain financing solutions that incorporate a financing component, such as accounts receivable (AR) factoring. These services offer higher margins and lower capital risk by leveraging a platform that arranges financing through third-party financial institutions rather than using Nisun International’s own capital.

“Our recalibration toward supply chain financing solutions is a direct response to market dynamics and our goal of delivering stronger, more sustainable results,” added Xin Liu. “We remain committed to innovation and operational excellence as we reposition our Company for the future.”

EXPANSION OF KFC BUSINESS ON COLLEGE CAMPUSES

Nisun International is also encouraged by the initial success of its KFC operations with its business partner on college campuses and plans to expand this business in the near term. The Company believes this initiative will serve as an additional growth driver, complementing its other core lines of business. For more details on the KFC business and its potential impact on Nisun International’s growth plans, please reference the Company’s upcoming filings and press releases.

OUTLOOK AND CONFIDENCE FOR 2025

With these strategic decisions and ongoing business successes, Nisun International is confident in its ability to return to growth in 2025. According to Xin Liu, “We are forging a bright path forward—committed to innovation, adaptability, and delivering value for our stakeholders.”

About Nisun International Enterprise Development Group Co., Ltd

Nisun International Enterprise Development Group Co., Ltd (NASDAQ: NISN) is a technology-driven, integrated supply chain solutions provider focused on transforming the corporate finance industry. Leveraging its industry experience, Nisun International is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, Nisun International provides users with professional solutions for technology supply chain management, technology asset routing, and digital transformation of tech and finance institutions, enabling the industry to strengthen and grow. At the same time, Nisun International continues to deepen the field of industry segmentation through industrial and financial integration. Focusing on industry-finance linkages, Nisun International aims to serve the upstream and downstream of the industrial supply chain while also assisting with supply-side sub-sector reform. For more information, please visit http://ir.nisun-international.com/

Cautionary Note Regarding Forward-Looking Statements

This press release contains information about Nisun International ‘s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Nisun International encourages you to review other factors that may affect its future results in Nisun International ‘s registration statement and in its other filings with the Securities and Exchange Commission. Nisun International assumes no obligation to update or revise its forward-looking statements as a result of new information, future events or otherwise, except as expressly required by applicable law.

Crypto Markets Lukewarm on Trump’s Inauguration: Bybit and Block Scholes Report

DUBAI, UAE, Jan. 24, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, released the latest weekly crypto derivatives report in collaboration with Block Scholes, recognizing crypto markets’ subdued bullish sentiment in an almost anti-climatic turn of events after Trump’s inauguration.

The 2025 presidential inauguration triggered a wild weekend of speculation with Trump family meme coins TRUMP and MELANIA, tilting derivative markets toward a bullish shift. However, the anticipated BTC-related executive orders failed to materialize, causing implied volatility to drop although realized volatility rose. Perpetual and options markets maintained high funding rates and a persistent bullish tilt, reflecting the complex speculative environment as crypto’s sunny expectations met political uncertainty.

Key Insights:

SOL’s Spotlight Moment: Trump’s issuance of “husband and wife” coins sparked an all-time high in Solana perpetual swaps, driven by traders anticipating crypto-friendly policies. The TRUMP meme coin’s launch on Solana DEXs elevated the network’s fee generation, symbolically positioning it above Ethereum competitors.

Sources: Bybit, Block Scholes
Sources: Bybit, Block Scholes

Derivatives Market Resilience: Perpetual swap funding rates remained neutral-to-bullish despite minimal crypto-positive inauguration announcements, with open interest showing stable positions. Derivatives markets viewed the event as just one of many potential catalyst opportunities.

BTC Options Speculation: Earlier anticipation of a potential strategic BTC reserve triggered significant short-tenor options positioning, resulting in robust call buying and the strongest at-the-money term structure inversion since the November 2024 election. While front-end volatility pricing has moderated, the strong skew toward out-of-the-money calls persists.

Access the full report, including detailed analysis of volatility trends, funding rates, and options market dynamics.

#Bybit / #TheCryptoArk /#BybitResearch

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 60 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer

SYDNEY, Jan. 24, 2025 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for 64Cu-SAR-bisPSMA for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions in patients with biochemical recurrence (BCR) of prostate cancer following definitive therapy.

This milestone builds on Clarity’s earlier receipt of an FTD for 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1]. These 2 FTDs enable the Company to accelerate the development of its comprehensive diagnostic program with this product.

The FDA’s FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs. For 64Cu-SAR-bisPSMA, it provides a number of product development advantages. The designation paves the way for a faster review process once Clarity submits its product approval applications. Additionally, it enables more frequent communication with the FDA, allowing for rapid resolution of queries during development. Furthermore, Clarity can submit completed sections of its application as they are ready, rather than waiting for the entire package to be finished before it can be lodged with the FDA. These benefits would reduce the review time needed to bring this innovative prostate cancer imaging agent to market, potentially improving diagnosis and treatment planning for patients sooner.

The FTD submission highlighted several advantages of 64Cu-SAR-bisPSMA over currently approved PSMA PET agents due to the bivalent structure of bisPSMA and the longer half-life of 64Cu (12.7 hours vs. <2 hours for 18F and 68Ga). These advantages include improved diagnostic performance, flexible imaging schedule and broader availability. The data for this FTD submission was primarily focused on the results of the Phase I/II COBRA study, which assessed the safety and diagnostic performance of 64Cu-SAR-bisPSMA in detecting prostate cancer in patients with BCR of their disease who had a negative or equivocal standard of care (SOC) scan at study entry. Advantages have been shown with same-day and next-day imaging, however, the standout was next-day 64Cu-SAR-bisPSMA PET imaging, showing localised disease in up to 80% of participants and detecting lesions as small as 2 mm. This compares favourably against the current SOC PSMA PET agents, with which the detection of lesions smaller than 5 mm is challenging. The number of lesions detected by 64Cu-SAR-bisPSMA on next-day imaging almost doubled compared to same-day imaging, and 64Cu-SAR-bisPSMA was also able to identify more lesions at much earlier timepoints compared to approved PSMA PET agents.

The COBRA trial paved the way for Clarity’s second diagnostic registrational trial, AMPLIFY, and an investigator-initiated trial (IIT) Co-PSMA, led by Prof Louise Emmett at St Vincent’s Hospital Sydney. The AMPLIFY trial will be a non-randomised, single-arm, open-label, multi-centre, Phase III diagnostic clinical trial of 64Cu-SAR-bisPSMA PET in approximately 220 participants with rising or detectable PSA after initial definitive treatment. As a pivotal trial, the final study results are intended to provide sufficient evidence to support an application to the FDA for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in prostate cancer in patients with BCR. The Co-PSMA IIT will aim to build on the evidence generated so far, evaluating the diagnostic performance of 64Cu-SAR-bisPSMA in comparison to SOC 68Ga-PSMA-11 for the detection of recurrent prostate cancer lesions with curative intent.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “Receiving the second FTD for 64Cu-SAR-bisPSMA and well within the 60-day period following our application submission, reserved by the U.S. FDA for review, is yet another significant milestone in our bisPSMA program. This highlights the high unmet need for novel diagnostics in prostate cancer and the high quality of data we presented to the FDA.

“The market for first-generation diagnostic PSMA PET today is approximately US$2 billion (AU$3.2 billion) in the U.S. alone, with little differentiation between products. It is expected to further grow to US$3 billion (AU$4.75 billion) by 2029. The development pipeline of new products coming to market, outside of 64Cu-SAR-bisPSMA, also offers no differentiation from the existing offering, with some new entrants commercialising the unpatented 68Ga-PSMA-11 agent, which has been capitalised on by three separate groups already.  

“Being able to now fast-track the development of 64Cu-SAR-bisPSMA for patients with BCR as well as for patients prior to initial definitive therapy is incredibly exciting. The news is especially timely as we are actively preparing to commence recruitment for our second registrational trial, AMPLIFY, in the coming months. The designation will allow us to work closely with the FDA to facilitate the development process and accelerate the approval of what could become a best-in-class diagnostic.

“The dual targeting structure of bisPSMA enables increased uptake and retention of the product in the lesions, while the longer half-life of copper-64 provides greater flexibility with imaging scheduling, including next-day imaging (something that gallium-68 and fluorine-18 based products cannot support). When combined, these features make 64Cu-SAR-bisPSMA stand out from its competitors who are known to have issues with sensitivity. We have seen 2-3 times higher uptake in prostate cancer lesions and the identification of more lesions using 64Cu-SAR-bisPSMA compared to 68Ga-PSMA-11 in pre-prostatectomy patients in our PROPELLER study. The COBRA trial results showed great diagnostic performance in the BCR setting, with lesions identified by 64Cu-SAR-bisPSMA in the 2-mm range and visualised many months before SOC PSMA PET agents are able detect them.

“Not only are we developing a product that may have improved diagnostic performance compared to SOC PSMA PET agents, but the longer half-life of copper-64 also enables a longer shelf-life of 64Cu-SAR-bisPSMA than currently used diagnostic radiopharmaceuticals, allowing for centralised manufacture and wider distribution. These attributes have the potential to reduce disparities in prostate cancer care and ensure that most patients, regardless of geographic location, can benefit from the latest advances in diagnostic technology.

“This designation highlights the unique opportunity for 64Cu-SAR-bisPSMA in this very large market by addressing the limitations of the current-generation diagnostic radiopharmaceuticals and providing patients with prostate cancer with a more accurate diagnosis leading to more optimal treatment options. As such, we are fully committed to advancing the development of this best-in-class product to address the critical need for more accurate and accessible diagnostic tools in prostate cancer management.”

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

64Cu-SAR-bisPSMA is an unregistered product. The safety and efficacy of 64Cu-SAR-bisPSMA has not been assessed by health authorities such as the U.S. FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available. Among 82 patients who received 64Cu-SAR-bisPSMA in PROPELLER and COBRA, 2 adverse reactions were reported in 2 participants (mild occasional metallic taste and moderate worsening of type II diabetes, both resolved)[2],[3].

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[4]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the U.S. and around 35,770 deaths from the disease[5].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers in children and adults. 
www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor                                                 

Catherine Strong

Executive Chairperson                                               

Investor/Media Relations

ataylor@claritypharm.com                                   

c.strong@morrowsodali.com

+61 406 759 268

 

References

[1] Clarity Pharmaceuticals. Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA. https://www.claritypharmaceuticals.com/news/fast-track/ 

[2] Lengyelova et al.  64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer. ASCO, 2023.

[3] Nordquist et al. COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy. EANM, 2024.

[4] Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834

[5] American Cancer Society: Key Statistics for Prostate Cancer, https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

This announcement has been authorised for release by the Executive Chairperson.

Nuevocor Welcomes Andreas Wallnöfer as Chairman of the Board of Directors

SINGAPORE and PHILADELPHIA, Jan. 24, 2025 /PRNewswire/ — Nuevocor, an IND-stage biotechnology company dedicated to developing functional cures to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment of Dr. Andreas Wallnöfer as Chairman of Nuevocor’s Board of Directors.   

Andreas Wallnöfer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team and nearly a decade serving as a board member for several biotechnology companies. He has been a Partner at the Swiss venture capital firm BioMedPartners and later at Jeito Capital, a global leading European investment company based in Paris.

An accomplished investor, board member and operator, Andreas has played a pivotal role in successfully developing many innovative companies. He has contributed to numerous successful exits, including the recent acquisition of EyeBio by MSD for a total deal value of US$3 billion, achieved only three years after the company’s inception.

Prior to his career in venture capital, he was Head of Cardiovascular and Metabolism (CVM) R&D at Roche and a member of the Roche/Genentech Portfolio Committee. Andreas was part of several successful product developments and market introductions. Before the integration of Genentech (now a wholly owned member of the Roche Group), Andreas was Global Head of Clinical Research and Exploratory Development and led the R&D organization at multiple sites in Europe, the U.S., and Asia. He had a key role in the integration of the Roche and Genentech development organizations and, subsequently, led Roche’s Early Development Department.

“We are extremely pleased to welcome Andreas as Chairman of Nuevocor’s Board and look forward to benefiting from his experience in life-sciences investment as well as expertise in cardiovascular diseases,” said Dr. Yann Chong Tan, PhD, CEO and Co-Founder of Nuevocor. “Having moved several companies towards successful exits, Andreas’ experience will be a major asset to Nuevocor as we continue to grow and demonstrate the value of our therapeutic assets in treating cardiomyopathies.”

“Nuevocor is at the frontier of next generation gene therapy. Particularly as former Head of Cardiovascular Research and Development at Roche, it is very motivating to see how Nuevocor’s promising technology may sustainably benefit and improve the lives of patients with cardiomyopathies” said Dr. Andreas Wallnöfer.

About Nuevocor

Nuevocor is a biotechnology company that is pioneering an innovative pathway-centric approach to developing functional cures for heart conditions known as cardiomyopathies. By harnessing our PrOSIA mechanobiology platform, Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases. Nuevocor’s approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables us to extend our impact to broader patient populations.

Akluer Celebrates 520 Dual-Sided Treadmill Milestone with Customer Appreciation Day

NEW YORK, Jan. 24, 2025 /PRNewswire/ — Akluer, the global leader in innovative fitness solutions, is excited to announce that its revolutionary 520 Dual-Sided Treadmill has sold over 5,000 units in its first month. To celebrate this achievement and thank our customers, Akluer will host a special discount event on January 28, 2025 to February 14, 2025. 

 

Akluer Dual-Sided Treadmill: The Top Health Gift Choice for 2025

Introducing the Akluer 520 Dual-Sided Treadmill

Akluer’s latest innovation is set to transform home fitness by integrating a treadmill and a foot massager into one stylish and space-saving device. The Akluer Treadmill is designed to cater to users of all ages and body types, making it an ideal addition to any household. Its multifunctional design not only saves space but also provides a seamless transition between high-intensity workouts and soothing relaxation sessions.

Akluer 520 Dual-Sided Treadmill (Original: $399.99, Special Discount: $139.99):

Fitness and Relaxation in One Space-Saving Device, combining fitness and relaxation in a versatile, modern design. Switch easily between running and foot massages, perfect for any home. The nature-inspired massage mimics cobblestone paths for a soothing experience. Four modes—Walking, Jogging, Massage, and Pet Walking—meet diverse needs. An 8-point shock absorption system protects knees and ankles, while a non-slip, 5-layer belt and double-layer frame ensure stability. Dual screens display speed, time, distance, calories, and massage settings. A 2.5HP motor supports up to 330 lbs, delivering stable, high-intensity performance. The Akluer Treadmill brings efficiency and comfort to every family.

Akluer’s Commitment to Innovation

Akluer is a global leader in fitness technology, dedicated to transforming the way people engage with health and wellness. The Akluer 520 Dual-Sided Treadmill is the latest testament to the brand’s commitment to bringing cutting-edge fitness solutions to homes worldwide.

Pricing and Availability

Customers who purchase the 520 Dual-Sided Treadmill during this period will receive a $260 discount and enjoy a one-year warranty.

The Akluer 520 Dual-Sided Treadmill is now available for purchase at a special price of $139.99 on the Akluer website (www.akluer.com). For more information about Akluer and its innovative products, visit their official website.

Akluer continues to push the boundaries of fitness technology, making health and wellness accessible and enjoyable for everyone. The Akluer Treadmill is more than just a fitness device; it’s a lifestyle choice that combines efficiency, innovation, and relaxation.

Akluer website: www.akluer.com
Youtube: www.youtube.com/@akluer
Ins : www.instagram.com/akluer_offical/
TK: www.tiktok.com/@akluer
Pinterest: www.pinterest.com/Akluer_official/
FB page: www.facebook.com/Akluer
FB group: www.facebook.com/groups/akluer

Media Contact: Bo Li, finn.mertens@akluer.com 

Akluer Dual-Sided Treadmill: The Top Health Gift Choice for 2025
Akluer Dual-Sided Treadmill: The Top Health Gift Choice for 2025

Winter Davos 2025: Yidu Tech Accelerates Global Expansion of AI-Powered Healthcare Solutions

DAVOS, Switzerland, Jan. 24, 2025 /PRNewswire/ — From January 20 to 24, the World Economic Forum Annual Meeting 2025, also known as Winter Davos, gathered global leaders in Davos, Switzerland. Representing China’s AI-powered healthcare sector, Ms. Gong Rujing(Yingying), Founder and Chairwoman of Yidu Tech and a distinguished Young Global Leader, actively participated in high-profile discussions, exchanging insights with leaders across government, business, and academia. She shared Yidu Tech’s groundbreaking practices and innovative solutions while addressing key challenges and opportunities in scaling digital health and fostering leadership resilience in uncertain times.

Ms. Gong Rujing (Yingying) Speaks at Davos
Ms. Gong Rujing (Yingying) Speaks at Davos

The Future of Digital Health: Opportunities and Challenges

On January 23, Ms. Gong participated in a panel discussion on scaling digital health solutions globally, alongside Italy’s Minister of Health Orazio Schillaci, H.E. Mansoor Al-Mansoori, Chairman of Abu Dhabi’s Department of Health, and Peter Sands, Executive Director of the Global Fund. Moderated by John Halamka, President of Mayo Clinic Platform, the discussion delved into practical strategies for advancing digital health systems, emphasizing the importance of trust, data standardization, and security.

Ms. Gong highlighted Yidu Tech’s role as a trailblazer in AI-powered healthcare innovation, having supported over 240 high-impact scientific publications, improved clinical trial efficiency by 40%, and served 34 million policyholders with tailored health insurance solutions. She emphasized that digital health is transforming healthcare ecosystems by enabling personalized care, smarter decision-making, and more sustainable healthcare systems.

Expanding Global Footprint

Yidu Tech has actively expanded into key international markets such as Southeast Asia and the United States, with plans to further enhance its presence in Japan, Europe, and other regions. Through its agile globalization strategy, Yidu Tech has demonstrated its ability to adapt to diverse regulatory and cultural landscapes while building strong partnerships.

“Operating in China’s competitive market has forged a team with unparalleled resilience and adaptability,” Ms. Gong remarked. “This foundation enables us to bring innovative AI-powered healthcare solutions to more regions, addressing global healthcare challenges with local relevance.”

Leadership Resilience in a Complex World

On January 24, Ms. Gong joined Wikipedia Founder Jimmy Wales and former Ecuadorian Vice President Otto Sonnenholzner in a discussion on leadership resilience in complex and rapidly changing environments. Drawing from Yidu Tech’s experiences, she shared how the company leveraged AI-powered tools to support epidemic prevention, optimize resource allocation, and accelerate the approval of life-saving treatments during the pandemic.

Ms. Gong also discussed Yidu Tech’s deployment of decentralized clinical trial (DCT) solutions, which significantly reduce costs and time for new drug development. Notably, the company supported the approval of China’s first 3CL-targeted COVID-19 antiviral, demonstrating its ability to drive innovation in critical healthcare areas.

Transforming Healthcare with AI-Powered Solutions

Since its founding, Yidu Tech has remained committed to tackling key healthcare challenges by delivering impactful solutions:

  • Population Health Management: Launched initiatives that support regional health systems and improve population well-being in cities like Beijing and Ningbo.
  • Provider Solutions: Empowered hospitals and healthcare organizations to improve operational efficiency and deliver better patient care.
  • Advancing Clinical Research: Facilitated scientific breakthroughs and improved the efficiency of drug development.
  • Insurance Innovation: Designed innovative products for high-risk populations, serving over 34 million policyholders through Huiminbao programs in China.

Through these initiatives, Yidu Tech has strengthened its position as a global leader in AI-powered healthcare, fostering innovation and driving meaningful progress across the healthcare ecosystem.

A Vision for the Future

Reflecting on her time at Davos, Ms. Gong expressed her pride in representing China’s AI-powered healthcare sector. “At Yidu Tech, our mission is to make precision healthcareaccessible to everyone b. We look forward to deepening our collaborations worldwide and contributing to the sustainable development of global healthcare.”

As Yidu Tech continues to expand its international presence, its commitment to collaboration and innovation ensures its role as a key partner in advancing healthcare for a healthier, more equitable world.

Sino Group and the Ng Teng Fong Charitable Foundation Launch ‘Community Care Chinese Medicine Service’ with Hong Kong Baptist University to Support the Well-Being of the Underprivileged

HONG KONG, Jan. 24, 2025 /PRNewswire/ — Sino Group (the ‘Group’), the Ng Teng Fong Charitable Foundation (‘NTFCF’), and the School of Chinese Medicine at Hong Kong Baptist University (‘HKBU’) are committed to the well-being of underprivileged members of the community and have recently launched the ‘Community Care Chinese Medicine Service’ programme. This initiative offers free Chinese medicine consultations and essential medications to members of the Community Living Room, aligning with its goal of enhancing health and quality of life by providing convenient and holistic support.

Professor Alex Wai, President and Vice-Chancellor of HKBU (second right), Ms Nikki Ng, Director of Philanthropy of Sino Group and Director of the Ng Teng Fong Charitable Foundation (second left), Professor Feng Sun, Director and Professor of Practice of the Clinical Division of School of Chinese Medicine, HKBU (first right) and Professor Junjun Yang, Executive Associate Director and Professor of Practice of the School of Chinese Medicine, HKBU (first left), hope to bring high-quality Traditional Chinese Medicine services to the community through the ‘Community Care Chinese Medicine Service’ programme.
Professor Alex Wai, President and Vice-Chancellor of HKBU (second right), Ms Nikki Ng, Director of Philanthropy of Sino Group and Director of the Ng Teng Fong Charitable Foundation (second left), Professor Feng Sun, Director and Professor of Practice of the Clinical Division of School of Chinese Medicine, HKBU (first right) and Professor Junjun Yang, Executive Associate Director and Professor of Practice of the School of Chinese Medicine, HKBU (first left), hope to bring high-quality Traditional Chinese Medicine services to the community through the ‘Community Care Chinese Medicine Service’ programme.

The ‘Community Care Chinese Medicine Service’ was launched in mid-August 2024 at the Sham Shui Po and Hung Hom Community Living Rooms. HKBU’s Chinese medicine team offers in-person consultations in the Community Living Rooms on a weekly basis, providing personalised health advice and Chinese medicine prescriptions tailored to each member’s lifestyle, psychological condition, and body constitution. Medications are delivered directly to the Community Living Rooms so that members can collect them conveniently.

Professor Alex Wai, President and Vice-Chancellor of HKBU, said, “The School of Chinese Medicine has an extensive Chinese medicine clinical network. With the donation support by Sino Group and the Ng Teng Fong Charitable Foundation, we can further expand our service locations, bringing our professional Chinese medicine services closer to the community and supporting the grassroots families. This initiative embodies HKBU’s spirit of helping the public with its expertise and benefiting more people in the community.”

Ms Nikki Ng, Director of Philanthropy of Sino Group and Director of the Ng Teng Fong Charitable Foundation, said, “We are committed to providing support to the community in various ways and are pleased to support the HKSAR Government’s Pilot Programme on Community Living Room by offering venues in Sham Shui Po and Hung Hom. This initiative enables us to reach those in need with services like festive visits and youth study tours. We are grateful for the positive reception received by the Chinese Medicine Services programme, in partnership with HKBU, and appreciate the practitioners’ attentive guidance, which has helped members improve their health and well-being. We would also like to extend our sincere gratitude to the two operators of the Community Living Rooms, the Lok Sin Tong Benevolent Society Kowloon and the Hong Kong Sheng Kung Hui Welfare Council, along with their teams, for their invaluable assistance and coordination.”

The Group’s concern for the well-being of members of the community extends to its employees. In addition to providing Traditional Chinese Medicine services to Community Living Room members, the Group invites the Chinese medicine team from HKBU to offer free consultations, check-ups with a four-diagnostic instrument, and health talks at various work locations. The advanced four-diagnostic instrument collects health data through face, togue and pulse diagnosis, as well as medical interviews, enabling Chinese medicine practitioners to assess employees’ physical conditions and develop personalised health management plans that address the diverse health needs of frontline staff.

Sino Group and the Ng Teng Fong Charitable Foundation Launch ‘Community Care Chinese Medicine Service’ with Hong Kong Baptist University to Support the Well-Being of the Underprivileged

HONG KONG, Jan. 24, 2025 /PRNewswire/ — Sino Group (the ‘Group’), the Ng Teng Fong Charitable Foundation (‘NTFCF’), and the School of Chinese Medicine at Hong Kong Baptist University (‘HKBU’) are committed to the well-being of underprivileged members of the community and have recently launched the ‘Community Care Chinese Medicine Service’ programme. This initiative offers free Chinese medicine consultations and essential medications to members of the Community Living Room, aligning with its goal of enhancing health and quality of life by providing convenient and holistic support.

Professor Alex Wai, President and Vice-Chancellor of HKBU (second right), Ms Nikki Ng, Director of Philanthropy of Sino Group and Director of the Ng Teng Fong Charitable Foundation (second left), Professor Feng Sun, Director and Professor of Practice of the Clinical Division of School of Chinese Medicine, HKBU (first right) and Professor Junjun Yang, Executive Associate Director and Professor of Practice of the School of Chinese Medicine, HKBU (first left), hope to bring high-quality Traditional Chinese Medicine services to the community through the ‘Community Care Chinese Medicine Service’ programme.
Professor Alex Wai, President and Vice-Chancellor of HKBU (second right), Ms Nikki Ng, Director of Philanthropy of Sino Group and Director of the Ng Teng Fong Charitable Foundation (second left), Professor Feng Sun, Director and Professor of Practice of the Clinical Division of School of Chinese Medicine, HKBU (first right) and Professor Junjun Yang, Executive Associate Director and Professor of Practice of the School of Chinese Medicine, HKBU (first left), hope to bring high-quality Traditional Chinese Medicine services to the community through the ‘Community Care Chinese Medicine Service’ programme.

The ‘Community Care Chinese Medicine Service’ was launched in mid-August 2024 at the Sham Shui Po and Hung Hom Community Living Rooms. HKBU’s Chinese medicine team offers in-person consultations in the Community Living Rooms on a weekly basis, providing personalised health advice and Chinese medicine prescriptions tailored to each member’s lifestyle, psychological condition, and body constitution. Medications are delivered directly to the Community Living Rooms so that members can collect them conveniently.

Professor Alex Wai, President and Vice-Chancellor of HKBU, said, “The School of Chinese Medicine has an extensive Chinese medicine clinical network. With the donation support by Sino Group and the Ng Teng Fong Charitable Foundation, we can further expand our service locations, bringing our professional Chinese medicine services closer to the community and supporting the grassroots families. This initiative embodies HKBU’s spirit of helping the public with its expertise and benefiting more people in the community.”

Ms Nikki Ng, Director of Philanthropy of Sino Group and Director of the Ng Teng Fong Charitable Foundation, said, “We are committed to providing support to the community in various ways and are pleased to support the HKSAR Government’s Pilot Programme on Community Living Room by offering venues in Sham Shui Po and Hung Hom. This initiative enables us to reach those in need with services like festive visits and youth study tours. We are grateful for the positive reception received by the Chinese Medicine Services programme, in partnership with HKBU, and appreciate the practitioners’ attentive guidance, which has helped members improve their health and well-being. We would also like to extend our sincere gratitude to the two operators of the Community Living Rooms, the Lok Sin Tong Benevolent Society Kowloon and the Hong Kong Sheng Kung Hui Welfare Council, along with their teams, for their invaluable assistance and coordination.”

The Group’s concern for the well-being of members of the community extends to its employees. In addition to providing Traditional Chinese Medicine services to Community Living Room members, the Group invites the Chinese medicine team from HKBU to offer free consultations, check-ups with a four-diagnostic instrument, and health talks at various work locations. The advanced four-diagnostic instrument collects health data through face, togue and pulse diagnosis, as well as medical interviews, enabling Chinese medicine practitioners to assess employees’ physical conditions and develop personalised health management plans that address the diverse health needs of frontline staff.